Navigation Links
Language, immigration status of hispanic caregivers impacted care of children with cancer

SAN DIEGO Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

"Ensuring good communication with patients and their families is as important as the actual therapy we give, regardless of what language is spoken," said Mark Fluchel, M.D., assistant professor in the department of pediatrics, division of hematology-oncology at the University of Utah Primary Children's Medical Center in Salt Lake City. "However, for families for whom there is a language and possibly a cultural barrier, extra care needs to be taken to make sure we are providing the best care possible."

Fluchel and his colleagues conducted a study among the primary caregivers of pediatric patients with cancer who were being treated at the University of Utah. Forty-six participants completed Spanish surveys and 323 completed English surveys. Caregivers evaluated various aspects of the child's care, such as how soon after recognizing a symptom they sought care, how satisfied they were with the care, and whether the child was in a clinical trial. The survey also assessed financial, emotional and language barriers to the child's care.

More than 65 percent of the Spanish-speaking respondents, defined as any caregiver who reported Spanish as their primary language, reported problems with their ability to speak English. Seventy percent of Spanish-speaking respondents reported that at least one member of their household had "undocumented" legal status. Thirteen percent reported avoiding or delaying care due to their immigration status.

When asked whether the child was enrolled in a clinical trial, 70 percent of Spanish-speaking caregivers and 40 percent of English-speaking caregivers reported that the child was enrolled in a clinical trial. However, when the researchers verified this information, they found that 32 percent of the Spanish-speaking and 12 percent of the English-speaking caregivers were incorrect about the child's enrollment. Researchers interpreted these findings as the caregivers not fully understanding the informed consent process.

More Spanish-speaking caregivers reported feeling that the potential side effects of therapy were not explained well compared with English speakers. However, Spanish-speaking participants were more satisfied with their child's overall care.

Among Spanish-speaking participants, 37 percent reported feeling not fully understood by the oncology staff, and 22 percent reported that they had falsely claimed understanding the oncology staff because they were embarrassed that they did not speak English. Eleven percent reported being uncomfortable asking for an interpreter, and 33 percent felt that their child would have received better care if English was their first language.

"As is the case with English speakers as well, we cannot assume that everything we say is understood," Fluchel said. "The most important thing we can do is to quickly establish a trusting relationship with patients and their families and make sure they are comfortable asking for clarification. Once that kind of relationship is established, I think communication errors are less likely."

Contact: Jeremy Moore
American Association for Cancer Research

Related medicine news :

1. Childrens health, access to care differ by parents immigrant status
2. Marital status, race increase survival rate significantly for Stage III non-small cell lung cancer patients
3. Study finds non-disclosure of HIV serostatus common among India female sex workers
4. Study examines chronic inflammation in oral cavity and HPV status of head and neck cancers
5. Study finds socioeconomic status linked to weight gain and risk of obesity in African-American women
6. Plavixs New Generic Status Could Be Boon for Patients
7. Disparities in treatment of children in the emergency department based on their insurance status
8. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
9. Cancer Overtakes Heart Disease as Top Cause of Death Among U.S. Hispanics
10. Report: Cancer now leading cause of death in US hispanics
11. Improved Developmental Screening Urged for Hispanic Kids
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: